Ann: Trading Update - H1 FY21, page-2

1ASX AnnouncementInterim Trading Update•H1 FY21 up 31% on H1 FY20 •Strong sales Q1 FY21 up 75% on Q1 FY20•Slower than expected sales in October and November•Strong December sales exceeded budget in US, NZ, and Taiwan New Accounts – Direct Markets- H1 FY21 opened 35 new accounts across all direct markets- CY20 opened 109 new accounts representing 89% growth on CY19- Strong platform growth during a pandemic evident by significant account acquisition United States- Q1 FY21 up 70% on Q1 FY20 - Q2 FY21 up 16% on Q2 FY20 - 1H FY21 up 41% on 1H FY21 - Sales for the month of December 2020 exceeded budget- Hired 12 experienced and dedicated Territory Managers and 1 Sales Director in 1H FY21- Received more Requests for Proposal (RFP) in last 3 months than previous 9 months- Signed two GPOs and a number of large strategic hospitals- Ongoing progress with GPO’s but has slowed due to COVID-19, however we expect to see movement in Q3 FY21- Participated in a few large IDN RFP’s and anticipate agreements in place in Q3 FY21- Expanded our military presence with the addition of Portsmouth Naval- Added a second account in Canada that has used BTM for a challenging case through the Health Canada Special Access Program- Webinars and virtual conferences are driving new accounts - Recruiting additional sales staff so further growth expected from new geographicsOther Countries- First sale to Taiwan in December and executed sales to Singapore, Finland and South Africa - New Zealand and Taiwan sales for the month of December 2020 exceeded budget- Entered new markets Greece, Belgium, Netherlands, Luxembourg, Sweden, Finland, and Taiwan- Our DACH/Benelux distributor has clinical evaluations in 30 new accounts underway- UK is building on its customer base with 6 clinical evaluations underway- First clinical evaluation performed in Ireland